GC
EBS icon

Guggenheim Capital’s Emergent Biosolutions EBS Stock Holding History

Guggenheim Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,247
Closed -$97.4K – 1856
2023
Q2 		$97.4K Sell
13,247
-4,737
-26% -$43.9K ﹤0.01% 1836
2023
Q1 		$186K Sell
17,984
-43,347
-71% -$524K ﹤0.01% 1815
2022
Q4 		$724K Buy
61,331
+21,785
+55% +$337K 0.01% 1321
2022
Q3 		$830K Sell
39,546
-1,673
-4% -$46.6K 0.01% 1231
2022
Q2 		$1.28M Sell
41,219
-44,573
-52% -$1.52M 0.01% 1113
2022
Q1 		$3.52M Buy
85,792
+680
+0.8% +$30K 0.02% 795
2021
Q4 		$3.7M Sell
85,112
-59,629
-41% -$2.7M 0.02% 800
2021
Q3 		$7.25M Sell
144,741
-7,201
-5% -$436K 0.04% 507
2021
Q2 		$9.57M Buy
151,942
+3,911
+3% +$251K 0.06% 407
2021
Q1 		$13.8M Buy
148,031
+1,446
+1% +$148K 0.09% 266
2020
Q4 		$13.1M Buy
146,585
+44,673
+44% +$4.1M 0.08% 254
2020
Q3 		$10.5M Sell
101,912
-26,744
-21% -$2.88M 0.08% 264
2020
Q2 		$10.2M Sell
128,656
-289
-0.2% -$21.5K 0.08% 266
2020
Q1 		$7.46M Sell
128,945
-250
-0.2% -$14.4K 0.08% 295
2019
Q4 		$6.97M Buy
129,195
+2,566
+2% +$139K 0.05% 464
2019
Q3 		$6.62M Buy
126,629
+6,625
+6% +$309K 0.05% 462
2019
Q2 		$5.8M Buy
120,004
+8,037
+7% +$385K 0.05% 522
2019
Q1 		$5.66M Sell
111,967
-11,925
-10% -$703K 0.05% 547
2018
Q4 		$7.34M Sell
123,892
-12,979
-9% -$837K 0.06% 375
2018
Q3 		$9.01M Sell
136,871
-84,583
-38% -$4.94M 0.06% 394
2018
Q2 		$11.2M Sell
221,454
-50,829
-19% -$2.65M 0.07% 305
2018
Q1 		$14.3M Sell
272,283
-66,635
-20% -$3.32M 0.04% 583
2017
Q4 		$15.8M Sell
338,918
-25,359
-7% -$1.07M 0.04% 566
2017
Q3 		$14.7M Sell
364,277
-122
-0% -$4.41K 0.03% 571
2017
Q2 		$12.4M Sell
364,399
-20,178
-5% -$623K 0.03% 606
2017
Q1 		$11.2M Sell
384,577
-3,813
-1% -$116K 0.03% 646
2016
Q4 		$12.8M Sell
388,390
-142,816
-27% -$4.28M 0.04% 593
2016
Q3 		$16.7M Buy
531,206
+12,037
+2% +$350K 0.05% 544
2016
Q2 		$14.6M Buy
519,169
+2,385
+0.5% +$93.5K 0.05% 562
2016
Q1 		$18.8M Sell
516,784
-14,173
-3% -$501K 0.06% 554
2015
Q4 		$21.2M Buy
530,957
+36,464
+7% +$1.27M 0.06% 548
2015
Q3 		$14.1M Sell
494,493
-125,695
-20% -$4.14M 0.04% 633
2015
Q2 		$20.4M Sell
620,188
-95,528
-13% -$2.96M 0.05% 609
2015
Q1 		$20.6M Sell
715,716
-39,786
-5% -$1.14M 0.05% 628
2014
Q4 		$20.6M Sell
755,502
-6,808
-0.9% -$162K 0.05% 629
2014
Q3 		$16.2M Buy
762,310
+396,001
+108% +$9.07M 0.04% 723
2014
Q2 		$8.23M Buy
366,309
+234,647
+178% +$5.47M 0.02% 939
2014
Q1 		$3.33M Buy
131,662
+2,224
+2% +$56.2K 0.01% 1391
2013
Q4 		$2.98M Sell
129,438
-274
-0.2% -$5.71K 0.01% 1434
2013
Q3 		$2.47M Buy
129,712
+3,892
+3% +$69.5K 0.01% 1475
2013
Q2 		$1.81M Buy
+125,820
New +$1.82M 0.01% 1596

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Guggenheim Capital's EBS Position: Q3 2023 in Review

Guggenheim Capital sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 13,247 shares — an estimated $97.4K sold.

Guggenheim Capital first reported a position in EBS in Q2 2013 and held it in 41 quarters. The position peaked at $21.2M in Q4 2015. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

  • Guggenheim Capital reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
  • Guggenheim Capital sold 13,247 Emergent Biosolutions shares in Q3 2023, an estimated $97.4K.
  • Guggenheim Capital first reported a position in Emergent Biosolutions in Q2 2013 and held it in 41 quarters.
  • Guggenheim Capital's Emergent Biosolutions position peaked at $21.2M in Q4 2015.
  • 162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Guggenheim Capital's 13F filing for Q3 2023, filed 14 Nov 2023.